Cancer Prevention and Treatment Fund的动态

"You really need to do something quite fundamentally different to either try and turn-off autoimmune disease or drive responses in oncology - which is why we’ve centered on manipulating that detection event (Signal 1)” Our CEO & Co-founder, Peter Joyce, speaks with Labiotech.eu on their Beyond Biotech podcast about our origins, clinical progress, and the potential of our approach in developing treatments for autoimmune diseases. Listen now ?? https://lnkd.in/eRwXZQBQ

AASLD #TLM24 ? This has been a big week for the team at Vir Biotechnology, Inc.. I am excited about the progress we have demonstrated in our clinical studies in #HepatitisDelta and #HepatitisB. Here's what you should know: ?? #HepatitisDelta is the most severe form of chronic viral hepatitis. There are no approved treatments in the U.S., and options are limited globally. We are working to change the narrative of what having hepatitis delta means. ?? We are excited about the encouraging results from our SOLSTICE Phase 2 trial in hepatitis delta. ?? ?? We are moving forward with ECLIPSE, a Phase 3 registrational clinical program that we plan to start in the first half of 2025. ?? #HepatitisB affects more than 250 million people who must settle for lifelong treatments that don’t eliminate the risk of disease progression to liver cancer. ? The data from our MARCH study brings us one step closer to our mission to deliver game-changing innovation to people living with #HepatitisB. ? Next up are the functional cure data in 2025, that will be decisive for the next steps of clinical development. I’m #VirProud of what we have achieved so far and look forward to our next steps.

According to a study presented at the annual meeting of the American Association for Cancer Research in April, researchers evaluated the effectiveness of mailed at-home self-sampling for HPV testing in a safety-net health system setting. "After U.S. Food and Drug Administration approval, self-sampling for high-risk-HPV testing has the potential to dramatically increase participation in cervical cancer screening in underserved populations," the authors wrote. Read more: https://lnkd.in/ePghxE6G #hpv #cervicalcancer

Confident MRD assessment for AML is now within reach with SOPHiA GENETICS DDM? RAM Solution. Experience ultra-sensitive detection, streamlined workflows, and confident MRD assessment. #NGS #MRD #AML?#Precisionmedicine #Bloodcancer #Bloodcancerawareness #Knowmyeloid

?? #ONCOnews ?? ?? FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer ?? The recommended ensartinib dose is 225 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. ?? https://buff.ly/3ZLZ7PC #OncEd #OncoAlert

Download this infographic, sponsored by PromoCell, which details the role of human leukocyte antigens in diseases like cancer and autoimmune diseases and how HLA-typed cells can offer advantages for personalized medicines and developing tailored treatments >>> https://hubs.ly/Q02ZGwYY0

mRNA technology has the potential to revolutionize therapeutic applications in the fight against cancer, cardiovascular, immunological and other infectious diseases. One major reason why this technology is so compelling is the ability to develop and scale innovative solutions rapidly. That's why choosing the right CDMO partner is so critical to reduce risks, costs and time associated with regulatory hold-ups, supply chain complexity and lack of technical expertise. And that's where we come in -- we're here to help you overcome these challenges and conquer the mRNA era with our integrated CDMO offering from mRNA synthesis to LNP formulation and fill-finish. Learn more. https://ms.spr.ly/6045jraYh

?? Despite some notable successes, there are still relatively few medicines approved for cancer prevention in healthy individuals. ?? This video reviews the progress in developing cancer prevention medicines and summarizes the challenges in this space. Furthermore, it outlines six key concepts that could accelerate drug development for cancer prevention: unmet clinical need, patient identification, risk stratification, pharmacological intervention, clinical trials, and health care policy. ?? These concepts, if realized, may help increase the number of available medicines for cancer prevention. Join the almost 6000 viewers here ==> https://lnkd.in/e3w5A3vn Amazing job Consilium Scientific #CancerPrevention #DrugDevelopment #HealthcareInnovation

According to Indus Health Plus’s retrospective analysis data (unpublished), around 2.3% of Indians are intermediate metabolizers of DPYD associated medications like 5-fluorouracil. 5-FU (fluorouracil) is commonly used in breast cancer treatment, especially in advanced stages or as part of combination therapies for adjuvant treatment. However, patients with decreased or non-functioning DPYD alleles may struggle to metabolize this drug effectively. This can lead to severe side effects such as nausea, vomiting, diarrhea, and even life-threatening bone marrow suppression. Genetic testing for DPYD can identify patients at risk, allowing for necessary dose adjustments and therapeutic drug monitoring to ensure safer, more effective treatment. Take action today! If you or someone you know is undergoing breast cancer treatment, consider getting tested. Protect your health and make informed decisions about your care. #HealthcareLeadership #BreastCancerAwareness #IndusHealthPlus #PinkOctober #DPYD #5FU #GeneticTesting

According to Indus Health Plus’s retrospective analysis data (unpublished), around 2.3% of Indians are intermediate metabolizers of DPYD associated medications like 5-fluorouracil. 5-FU (fluorouracil) is commonly used in breast cancer treatment, especially in advanced stages or as part of combination therapies for adjuvant treatment. However, patients with decreased or non-functioning DPYD alleles may struggle to metabolize this drug effectively. This can lead to severe side effects such as nausea, vomiting, diarrhea, and even life-threatening bone marrow suppression. Genetic testing for DPYD can identify patients at risk, allowing for necessary dose adjustments and therapeutic drug monitoring to ensure safer, more effective treatment. Take action today! If you or someone you know is undergoing breast cancer treatment, consider getting tested. Protect your health and make informed decisions about your care. #HealthcareLeadership #BreastCancerAwareness #IndusHealthPlus #PinkOctober #DPYD #5FU #GeneticTesting #KnowBetterLiveBetter